immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Centre Hospitalier Régional Universitaire De Besançon is a private company headquartered in France that operates hospital.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark.

Amager and Hvidovre Hospital is all about life. Life is about saving lives and giving life to the world. The quality of life for the patients and a good working environment for the employees. They Are ready with expertise and care around the clock. It is important for the patient to transition quickly from diagnosis to treatment and to return safely to everyday life. They act competently and carefully, even when life is at its worst. They are experts in folk diseases - the diseases that most people suffer from. In addition, they can provide highly specialized treatment to patients with rare diseases. They are proud of both. The work of hundreds of researchers every day is vital to the improvement and saving of lives. They develop and share new knowledge - it creates strong professional environments. The professionalism and development of all employees ensures good treatment of patients and an exciting working environment.

Infinitus (China) Co., Ltd., a subsidiary of Lee Kum Kee Group Ltd., is a company headquartered in Guangzhou, China, that develops, manufactures and distributes herbal health products.\nThe company says this about itself: Founded in 1992, Infinitus, a member of LKK Health Products Group, is a modern large-scale company that specializes in R&D, production, sales and services of Chinese herbal health products.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Hangzhou Jiemeng Disease Prevention and Control Technology Co., Ltd., established on 2010-04-28, Business scope includes services:Animal disease joint prevention and control technology,Biotechnology,Veterinary Technology,Diagnostic reagents,Veterinary and food safety test card(strip),Technical development of laboratory instruments,technical consulting,Technical Services,Achievement transfer,Research and development of animal husbandry technology products,computer network engineering,Computer software development and technology transfer,Non-Certificate Labor Occupational Skills Training for Adults(Except for projects involving pre-approval),Dedicated transport of goods(Refrigerated)(Operate with a valid license);wholesale,retail:Laboratory Instruments and Consumables,laboratory reagent(In addition to pathology,Medical and diagnostic equipment and reagents,factory laboratory),Office Supplies,First,Class II medical device,Class III medical devices(Operate with a valid license),veterinary medicine(Operate with a valid license),Biological product,General Labor Insurance,electronic product(Except for electronic publications),department store,Animal Feeding Equipment,feed,Feed additives;All other legal items that do not need to be submitted for approval.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Harbin Veken Biotechnology Co., Ltd., established on 1992-10-27, The scope of business includes the development of bioengineering technology and products,Production,Sales and Technical Consulting,Technical Services;Sales of ancillary products related to development projects(Products not subject to country restrictions);Engage in import and export business within the scope approved by the import and export enterprise qualification certificate;Car rental;Technology Development for Livestock Raising;Technical Services for Laboratory Animals;Sales:birds,Egg,Agricultural and sideline products.Experimental animal management;animal husbandry;Animal epidemic prevention;Food production and operation;Veterinary drug business.The following are limited to branch operations:Diagnosis and treatment of animal diseases.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Beijing Gangsheng Pharmaceutical Technology Co., Ltd., established on 2009-10-19, Business scope includes pharmaceutical,Health food technology development,transfer,consult,Serve;plant medicinal herbs;produce food(Restricted to engage in production and business activities in other cities).(Enterprises independently choose operating projects according to law,Carry out business activities;and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Intervet International BV engages in the manufacture and marketing of animal health products. It offers vaccines, anti-infectives, anti-parasitics, feed additives and products for fertility management. The firm products are used for treatment and care of poultry, pigs, cattle, sheep, goats, horses, fish, shrimp and companion animals. The company was founded by Wim Hendrix in 1949 and is headquartered in Boxmeer, the Netherlands.

Shenzhen Hengtai Life Science and Technology Development Co., Ltd., established on 2017-05-24, Business scope includes general business items:Research and development of gene technology related products,Consulting and Services,Biotechnology Consulting and Services,Research and development of biological products,Research and development, purchase and sales of biological detection instruments,Purchase and sale of Class I medical devices;Consulting and service of life science technology,Health management consulting and services(Does not contain medical behavior),Domestic Trade(Does not contain franchise,Exclusive control,Monopoly);Operating import and export business.(All of the above are related to the law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:

They are a pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach. Our antibodies bind only to specific immunosuppressive proteins that are released from cancer cells (soluble ligands), and not to the cell surface-bound versions. This treatment is predicted to be effective towards multiple types of cancers and has safety built into the design of the drug, thereby minimizing the likelihood of unwanted side effects. Our current studies have demonstrated efficacy in repeated prostate cancer models in mice.

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer peptide vaccines, which constitute one form of cancer immunotherapy. It has developed ITK-1, a cancer peptide vaccine, which is in phase III clinical study to treat prostate cancer; and GRN-1201 that is in phase II clinical study for the treatment of non-small cell lung cancer, as well as in phase I clinical study to treat melanoma. The company’s products include GRN-1301, a drug resistant tumor-derived neo-antigen for the treatment of non-small cell lung cancer; and iPS-NKT, an induced pluripotent stem cell derived regenerated NKT cell therapy. BrightPath Biotherapeutics was founded by Ito Kyogo on May 8, 2003 and is headquartered in Kanagawa, Japan.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Foshan Standard Biotech Co., Ltd., part of Wen's Foodstuff Group Co., Ltd., is a Chinese company located in Foshan that develops and manufactures animal healthcare products. The firm was acquired by Guangdong Dahuanong Animal Health Products Co. Ltd., part of Wen's Foodstuff Group Co., Ltd. since November 2015, on March 15, 2013 for $24.89 million.